"It's our biggest win to date, without a doubt, " team chief executive Jonathan Vaughters said Wednesday from Denver, where he had just returned to from Europe.
So despite having a drug in front of the FDA, AVEO is currently a negative return for its venture investors (the ones who have held large portions to date) or at most a marginal win (1.3x) for those that exited in 2011 (looks like Flagship has exited, whereas MPM, Highland have been holding at least some of their positions).